Rifampicin reduced the AUC of aprepitant by 91%, and reduced efficacy would be expected. Fosaprepitant, a prodrug of aprepitant, would be expected to interact similarly. The UK manufacturer recommends that concurrent use should be avoided.
(22)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.